ロード中...
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
Background: YYB101, a humanized monoclonal antibody against hepatocyte growth factor (HGF), has shown safety and efficacy in vitro and in vivo . This is a first-in-human trial of this antibody. Materials and Methods: YYB101 was administered intravenously to refractory cancer patients once every 4 we...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publishing
2020-06-01
|
| シリーズ: | Therapeutic Advances in Medical Oncology |
| オンライン･アクセス: | https://doi.org/10.1177/1758835920926796 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|